1
|
Motley J, Stamps BW, Mitchell CA, Thompson AT, Cross J, You J, Powell DR, Stevenson BS, Cichewicz RH. Opportunistic Sampling of Roadkill as an Entry Point to Accessing Natural Products Assembled by Bacteria Associated with Non-anthropoidal Mammalian Microbiomes. J Nat Prod 2017; 80:598-608. [PMID: 28335605 PMCID: PMC5368682 DOI: 10.1021/acs.jnatprod.6b00772] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Indexed: 05/09/2023]
Abstract
Few secondary metabolites have been reported from mammalian microbiome bacteria despite the large numbers of diverse taxa that inhabit warm-blooded higher vertebrates. As a means to investigate natural products from these microorganisms, an opportunistic sampling protocol was developed, which focused on exploring bacteria isolated from roadkill mammals. This initiative was made possible through the establishment of a newly created discovery pipeline, which couples laser ablation electrospray ionization mass spectrometry (LAESIMS) with bioassay testing, to target biologically active metabolites from microbiome-associated bacteria. To illustrate this process, this report focuses on samples obtained from the ear of a roadkill opossum (Dideiphis virginiana) as the source of two bacterial isolates (Pseudomonas sp. and Serratia sp.) that produced several new and known cyclic lipodepsipeptides (viscosin and serrawettins, respectively). These natural products inhibited biofilm formation by the human pathogenic yeast Candida albicans at concentrations well below those required to inhibit yeast viability. Phylogenetic analysis of 16S rRNA gene sequence libraries revealed the presence of diverse microbial communities associated with different sites throughout the opossum carcass. A putative biosynthetic pathway responsible for the production of the new serrawettin analogues was identified by sequencing the genome of the Serratia sp. isolate. This study provides a functional roadmap to carrying out the systematic investigation of the genomic, microbiological, and chemical parameters related to the production of natural products made by bacteria associated with non-anthropoidal mammalian microbiomes. Discoveries emerging from these studies are anticipated to provide a working framework for efforts aimed at augmenting microbiomes to deliver beneficial natural products to a host.
Collapse
Affiliation(s)
- Jeremy
L. Motley
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Blake W. Stamps
- Department
of Microbiology and Plant Biology, University
of Oklahoma, Norman, Oklahoma 73019-0390, United States
| | - Carter A. Mitchell
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Alec T. Thompson
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Jayson Cross
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Jianlan You
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Douglas R. Powell
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Bradley S. Stevenson
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
- Department
of Microbiology and Plant Biology, University
of Oklahoma, Norman, Oklahoma 73019-0390, United States
| | - Robert H. Cichewicz
- Natural
Products Discovery Group, Department of Chemistry and Biochemistry, and Institute for
Natural Products Applications and Research Technologies, Stephenson
Life Sciences Research Center, University
of Oklahoma, Norman, Oklahoma 73019-5251, United States
| |
Collapse
|
2
|
Abstract
The improved prognosis of cystic fibrosis (CF) over the last three decades has been associated with an increased use of a range of treatments, but it is important that the use of an individual treatment is based on evidence. Well-designed randomized controlled trials (RCTs) are a robust method for evaluating the effectiveness of such treatments. We have developed a register of RCTs in CF and have studied when they were performed, their design, and what interventions were investigated. We identified 506 RCTs; 37.5% were identified solely as abstract reports in conference proceedings. There has been about a 30-fold increase in the number of RCTs in CF since 1966. A high proportion of the RCTs (72.7%) had a sample size of 30 or less, and only 8.7% were multicenter trials. Reporting of study design was poor: in 51.4% the report did not state whether there was any blinding in the trial design; 53.6% of studies were of crossover design. The most common interventions studied were antibiotic treatments and physiotherapy, but a number of commonly used therapies had been evaluated only in a small number of patients. Although the number of RCTs of interventions in CF patients has increased over the last 25 years, the sample sizes of these trials are generally too small to indicate whether the intervention was effective, and very few were multicenter. Future RCTs in CF are more likely to provide clinically useful answers if higher numbers of patients are recruited into large, well-designed multicenter trials. This should be a priority of the organization of future research in CF.
Collapse
Affiliation(s)
- K Cheng
- Respiratory Unit, University Institute of Child Health, Alder Hey Children's Hospital, Liverpool, United Kingdom
| | | | | | | | | |
Collapse
|
4
|
Ellwood P, Durenberger D, Motley J, Riley T, Atkins L, Pollack R, Karrh BW, Gradison W, Enthoven A, Lehnhard MN. Health reform: what to expect from the coming debate. Interview by Jeannie Mankelker, Dan Wise, and Steven Findlay. Bus Health 1994; 12:26-8, 30, 32 passim. [PMID: 10139240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Health care reform is in limbo as 1994 draws to a close. Last month's Republican sweep puts the issue in a starkly new political environment. The new Congressional leadership said last month it will put forth a reform plan in 1995. Also, the Clinton administration is working on a scaled-back proposal. To get an idea of what might happen next year, we invited 20 informed persons to give us their opinions and to tell us what action they'd prefer. Because of B&H's production schedule, the interviews took place before the election. We don't think that diminishes their insights and analyses.
Collapse
|